Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1991 Jan 1;173(1):193–196. doi: 10.1084/jem.173.1.193

Inducibility of class II major histocompatibility complex antigens by interferon gamma is associated with reduced tumorigenicity in C3H mouse fibroblasts transformed by v-Ki-ras

PMCID: PMC2118749  PMID: 1898659

Abstract

Paired lines of C3H mouse fibroblasts transformed with murine sarcoma virus (Kirsten strain) were prepared that express high or low levels of class II major histocompatibility complex antigen after treatment with interferon gamma (IFN-gamma). Here, we described a comparison of the tumorigenicity of these lines in euthymic syngeneic and thymus- deficient nu/nu mice and in mice depleted of IFN-gamma. The class II- inducible cells are clearly less tumorigenic than the noninducible cells in syngeneic mice, but of similar tumorigenicity in nu/nu mice and in mice treated with antibodies to deplete IFN-gamma. We propose that in this system, IFN-gamma induction of class II antigens on the tumor cell surface operates to limit tumor growth; ras expression, which inhibits induction of class II antigens, prevents this and so allows tumor growth.

Full Text

The Full Text of this article is available as a PDF (371.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bateman W. J., Jenkinson E. J., Owen J. J. T-cell immunity to murine Moloney sarcoma virus-induced tumours: L3T4+ T cells are necessary for resistance to primary sarcoma growth, but Lyt-2+ T cells are required for resistance to secondary tumour cell challenge. Immunology. 1987 Jul;61(3):317–320. [PMC free article] [PubMed] [Google Scholar]
  2. Becker S. Interferon-gamma accelerates immune proliferation via its effect on monocyte HLA-DR expression. Cell Immunol. 1985 Mar;91(1):301–307. doi: 10.1016/0008-8749(85)90053-x. [DOI] [PubMed] [Google Scholar]
  3. Bernards R., Schrier P. I., Houweling A., Bos J. L., van der Eb A. J., Zijlstra M., Melief C. J. Tumorigenicity of cells transformed by adenovirus type 12 by evasion of T-cell immunity. 1983 Oct 27-Nov 2Nature. 305(5937):776–779. doi: 10.1038/305776a0. [DOI] [PubMed] [Google Scholar]
  4. Bos J. L., Fearon E. R., Hamilton S. R., Verlaan-de Vries M., van Boom J. H., van der Eb A. J., Vogelstein B. Prevalence of ras gene mutations in human colorectal cancers. 1987 May 28-Jun 3Nature. 327(6120):293–297. doi: 10.1038/327293a0. [DOI] [PubMed] [Google Scholar]
  5. Goodenow R. S., Vogel J. M., Linsk R. L. Histocompatibility antigens on murine tumors. Science. 1985 Nov 15;230(4727):777–783. doi: 10.1126/science.2997918. [DOI] [PubMed] [Google Scholar]
  6. Hämmerling G. J., Klar D., Pülm W., Momburg F., Moldenhauer G. The influence of major histocompatibility complex class I antigens on tumor growth and metastasis. Biochim Biophys Acta. 1987 Nov 25;907(3):245–259. doi: 10.1016/0304-419x(87)90008-4. [DOI] [PubMed] [Google Scholar]
  7. Infante A. J., Boulware S., Cagle M. L3T4+ T cells regulate Abelson virus-induced lymphomagenesis. J Immunol. 1988 Apr 1;140(7):2462–2465. [PubMed] [Google Scholar]
  8. Liu E., Hjelle B., Morgan R., Hecht F., Bishop J. M. Mutations of the Kirsten-ras proto-oncogene in human preleukaemia. Nature. 1987 Nov 12;330(6144):186–188. doi: 10.1038/330186a0. [DOI] [PubMed] [Google Scholar]
  9. Mann R., Mulligan R. C., Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell. 1983 May;33(1):153–159. doi: 10.1016/0092-8674(83)90344-6. [DOI] [PubMed] [Google Scholar]
  10. Maudsley D. J., Morris A. G. Kirsten murine sarcoma virus abolishes interferon gamma-induced class II but not class I major histocompatibility antigen expression in a murine fibroblast line. J Exp Med. 1988 Feb 1;167(2):706–711. doi: 10.1084/jem.167.2.706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Morris A. G., Ward G. A., Bateman W. J. Interaction of v-Ki-ras oncogene and interferon-gamma in the control of histocompatibility antigen expression in mouse fibroblasts. Cell Immunol. 1989 May;120(2):470–476. doi: 10.1016/0008-8749(89)90214-1. [DOI] [PubMed] [Google Scholar]
  12. Norton J. D., Connor J., Avery R. J. Genesis of Kirsten murine sarcoma virus: sequence analysis reveals recombination points and potential leukaemogenic determinant on parental leukaemia virus genome. Nucleic Acids Res. 1984 Sep 11;12(17):6839–6852. doi: 10.1093/nar/12.17.6839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ohnishi K., Bonavida B. Regulation of Ia+ reticulum cell sarcoma (RCS) growth in syngeneic SJL/J mice. I. Inhibition of tumor growth by passive administration of L3T4 monoclonal antibody before or after tumor inoculation. J Immunol. 1987 Jun 15;138(12):4524–4529. [PubMed] [Google Scholar]
  14. Ostrand-Rosenberg S., Thakur A., Clements V. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol. 1990 May 15;144(10):4068–4071. [PubMed] [Google Scholar]
  15. Schrier P. I., Bernards R., Vaessen R. T., Houweling A., van der Eb A. J. Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells. 1983 Oct 27-Nov 2Nature. 305(5937):771–775. doi: 10.1038/305771a0. [DOI] [PubMed] [Google Scholar]
  16. Spitalny G. L., Havell E. A. Monoclonal antibody to murine gamma interferon inhibits lymphokine-induced antiviral and macrophage tumoricidal activities. J Exp Med. 1984 May 1;159(5):1560–1565. doi: 10.1084/jem.159.5.1560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Tomkins P. T., Ward G. A., Morris A. G. Role of interferon-gamma in T-cell responses to Semliki Forest virus-infected murine brain cells. Immunology. 1988 Mar;63(3):355–362. [PMC free article] [PubMed] [Google Scholar]
  18. Vignaux F., Gresser I. Differential effects of interferon on the expression of H-2K, H-2D, and Ia antigens on mouse lymphocytes. J Immunol. 1977 Feb;118(2):721–723. [PubMed] [Google Scholar]
  19. Wallich R., Bulbuc N., Hämmerling G. J., Katzav S., Segal S., Feldman M. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature. 1985 May 23;315(6017):301–305. doi: 10.1038/315301a0. [DOI] [PubMed] [Google Scholar]
  20. Wong G. H., Bartlett P. F., Clark-Lewis I., Battye F., Schrader J. W. Inducible expression of H-2 and Ia antigens on brain cells. Nature. 1984 Aug 23;310(5979):688–691. doi: 10.1038/310688a0. [DOI] [PubMed] [Google Scholar]
  21. Yeoman H., Robins R. A. The effect of interferon-gamma treatment of rat tumour cells on their susceptibility to natural killer cell, macrophage and cytotoxic T-cell killing. Immunology. 1988 Feb;63(2):291–297. [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES